The findings, published in The Lancet Respiratory Medicine, suggest that dupilumab, when used alongside standard triple ...

Atopic dermatitis (AD) is a very common, heterogeneous and debilitating disease with a need for new treatment options CAN10 ...

First quarter 2025 revenues of $3.0 billion; GAAP diluted EPS of $7.27 and non-GAAP diluted EPS(a) of $8.22First quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 19% to $3.67 bil ...

The Company announced a 10-year agreement with FUJIFILM Diosynth Biotechnologies (Fujifilm) to manufacture and supply Regeneron's commercial bulk drug product at Fujifilm's North Carolina campus. The ...